Thursday, 18 August 2022
CIRSE 2022 Program Highlights
CIRSE was last in person in 2019 - also in Barcelona. If you share the same interests as us at CASCINATION - improving tumour ablation - we have taken some time to highlight the most relevant scientific topics and outline them for you here - complete with the moderators, speakers, rooms and calendar invites as well. We hope this is a great supplement for you to utilize in conjunction with the CIRSE App.
Saturday Sept 10th
FS 105 - Renal cancer management
8:30-9:30 Room 115- Moderators: D. Breen, O. Graumann
- 105.1 Patient selection - R. Grasso
- 105.2 Treatment planning - A. van Erkel
- 105.3 Percutaneous ablation - E. Galvez Gonzalez
- 105.4 Combined treatments - M. van Strijen
Download calendar invite
ERT 205 - Oligometastatic disease
10:00-11:00 Auditorium 1 - Moderators: M. Burgmans, A. Denys
- 205.1 What is the oncological evidence? Speaker TBA
- 205.2 Catching the right moment - oncology vs imaging - D. Regge
- 205.3 Local ablation vs. surgery - same effect, less time? M. Meijerink
Download calendar invite
FS 605 - HCC - changing the therapy paradigm?
16:15-17:15 Auditorium 2 - Moderators: A. Bojnovic, T. Helmberger
- 605.1 Surgery/LTx versus thermal ablation in early HCC - M. Meijerink
Sunday Sept 11th
CBD 1005 - Personalised approach in HCC treatment
10:00-11:00 Room 116 - Moderators: M. Reig, P. Pereira
- 1005.1 Uni-nodular HCC 3-5cm - L. Crocetti
- 1005.2 Uni-nodular HCC > 5cm - L. Tselikas
- 1005.3 Multi-nodular: out of Milan, inside UCSF - B. Peynircioglu
- 1005.4 Uni-nodular with vascular invasion - J. Ricke
SY 1307 - CASCINATION - Quality Ablation with CAS-One IR - Technology. Evidence. Economics
14:30-15:30 Room 115 - Moderators: L. Crocetti
- 1307.1 CAS-One IR - Current and future technology - N. Shaida
- 1307.2 CAS-One IR - The evidence landscape - M. Beermann
- 1307.3 CAS-One IR - Economic value - L. Luerken
SP 1504 - Image guided therapies
17:30-18:30 Room 115 - Moderators: B. Wood
- 1504.1 Early experience in routine practice with a navigated robotic arm for image-guided percutaneous needle insertion - T. de Baere
- 1504.2 Recommended optimal thermal ablation margin range model for liver malignancies ≤ 3cm based on 979 cases - Z. Qiu
- 1504.4 Percutaneous ablation of local and nodal prostate cancer recurrence: a single-center experience - F. Ridouani
- 1504.5 Intraprocedural assessment of ablation margins using computer tomography co-registration in primary liver tumor treatment with percutaneous ablation: IAMCOMPLETE study - P. Hendriks
- 1504.7 Percutaneous ablation of the adrenal lodge tumors - M. Blain
Monday Sept 12th
FC 1703 - Pulmonary tumours: where do we stand
8:30-9:30 Room 115 - Moderators: C. Sofocleous, T. de Baere
- 1703.1 What are the indications? A. Veltri
- 1703.2 Which image guidance to use? - T. Iguchi
- 1703.3 Which ablation techniques? - J. Palussiere
- 1703.4 Which follow-up protocols? - A. Larici
FS 1803 - Pancreatic cancer management
10:00-11:00 Room 117 - Moderators: C. Rountas, K. van Lienden
- 1803.1 Biopsy - B. Gebauer
- 1803.2 IRE - J. Abadal Villayandre
IRT 1806 - IR: The most tech of the medical specialities
10:00-11:00 Room 114 - Moderators: A. Bibok
- 1806.1 AI: what's already here and what will happen in a few years - F. Gomez Muñoz
- 1806.2 VR: what's already here and what will happen in a few years - B. Wood
- 1806.3 What are the expected benefits/constraints of tech developments for IR - L. Solbiati
MPI 2001 - Clinical trials in embolotherapy and interventional oncology: Meet the PI
13:00-14:00 News on stage - Moderators: L. Solbiati
- 2001.2 RESPECT: a new Europe-wide prospective multi-center observational study evaluating the effectiveness of percutaneous electrochemotherapy for liver cancer - A. Kovacs, P. Wiggerman
- 2001.3 A multi-center, single-arm, non-randomized, prospective European trial to evaluate the safety and efficacy of the Histosonics system in the treatment of primary and metastatic liver cancers - T. Wah
SP 2205 - Various oncologic interventions
16:15-17:15 Room 113 - Moderators: N. Goldberg, G. Carrafiello
- 2205.1 Oncological and peri-operative outcomes of cryoablation of renal cell carcinoma for patients with heriditary RCC diseases - an analysis of European multinational prospective EuRECA registry - W. Chan
- 2205.2 Outcome evaluation of percutaneous cryoablation for the treatment of primary and metastatic lun lesions: preliminary results from a Greek multicenter trial - D. Stefanou
- 2205.3 Cryoablation of breast cancer in metastatic patients: a dingle institutional experience - C. Pusceddu
- 2205.4 Percutaneous cryoablation for local tumor control of sarcoma pulmonary metastases in oligometastatic patients - E. Efthymiou
16:15-17:15 Room 114 - Moderators: L. Crocetti, P. Bruners
- 2206.1 Targeted exome-based predictors of progression patters of patients with colorectal liver metastases after percutaneous thermal ablation - I. Paolucci
- 2206.2 Minimum ablation margin assessment of colorectal liver metastases after using a novel AI-based automatic segmentation and biomechanical deformable registration - B. Odisio
- 2206.3 First look into CIEMAR: patient selection, treatment details and early safety data of the European-wide observational study on MWA in CRLM with curative intent - M. Meijerink
- 2206.4 Local vs. distant progression following thermal ablation of colorectal liver metastases - what is worse? - I. Paolucci
- 2206.5 Interventional oncological treatment of colorectal cancer in liver metastases (CRLM) - single center long-term evaluation over 26 years using thermoablative techniques in a multimodal application - T. Vogl
- 2206.6 Evaluation of tissue shrinkage after CT-guided microwave ablation of liver tumors using Jacobian determinant - G. Pöhler
FS 2203 - Cryoablation of benign soft tissue pathologies
16:15-17:15 Room 117 - Moderators: TBA
- 2203.1 Cryoablation of symptomatic neuroma - K. Ringe
- 2203.2 New guidelines of desmoid tumour management - J. Kurtz
- 2203.3 Cryoablation of desmoid tumours - R. Cazzato
- 2203.4 Pitfalls and complications to avoid - B. Welch
WS 2303 - Tips and tricks in ablation for lung metastases
17:30-18:30 Room 120 - Moderators: TBA
- 2303.1 Tips and tricks in ablation for lung metastases - E. Bozzi
- 2303.2 Tips and tricks in ablation for lung metastases - E. Bozzi
Tuesday Sept 13th
FS 2504 - Advanced technology in IO
8:30-9:30 Room 112 - Moderators: U. Pua
- 2504.1 Fusion imaging, navigation, and planning - R. Bale
- 2504.2 AI in IO - B. Meyer
- 2504.3 Augmented reality - L. Solbiati
- 2504.4 Robotics - N. Goldberg
ERT 2604 - How to treat stage A HCC outside the Milan criteria
10:00-11:00 Room 117 - Moderators: J. Ricke
- 2604.1 MWA - R. Duran
- 2604.2 Multiple electrode technique - R. Bale
- 2604.3 Combined treatments - J. Urbano Garcia
WS 3004 - Tips and tricks in ablation for liver metastases
16:15-17:15 Room 113 - Moderators: TBD
- 3004.1 Tips and tricks in ablation for liver metastases - R. Pujik
- 3004.2 Tips and tricks in ablation for liver metastases - H. Scheffer
Wednesday Sept 14th
FS 3203 - Robotic and stereotactic approaches in IR
8:30-9:30 Room 115 - Moderators: L. Lönn, L. Monfardini
- 3203.1 Simulation in IR - I. Brennan
- 3203.2 Robotic ablation - P. Wiggerman
- 3203.4 The impact of robotics on my practice - C. von zur Mühlen
10:00-11:00 Room 112 - Moderators: A. Hatzidakis, A. Gangi
- 3303.1 IR as a clinical specialty - O. van Delden
- 3303.2 Challenges in training future IRs - G. Goh
- 3303.3 Challenges in recognition - M. Lee
- 3303.4 Turf wars: lessons from the US - J. Kaufman
- 3303.5 Round-table discussion, followed by conclusion and take-home points
FS 3302 - Bone tumour management
10:00-11:00 Room 115 - Moderators: A. Kelekis, J. Garnon
- 3302.1 Benign bone tumours - D. Filippiadis
- 3302.2 Bone metastases - X. Buy
- 3302.3 Ablation and consolidation - F. Deschamps
- 3302.4 Pitfalls and complications to avoid - G. Tsoumakidou